Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 5

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 3Head & Neck 3Gastrointestinal 2Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × CF regimen × Lymphoid × Clear all
NCT05370547 2024-03-06

Chidamide Bridging for CAR-T Therapy

Chinese PLA General Hospital

Phase 1/2 Unknown
120 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04767308 2021-02-23

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Huazhong University of Science and Technology

Phase EARLY_PHASE1 Unknown
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
20 enrolled
Lymphoid

Hodgkin Disease

NCT04666168 2020-12-14

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
200 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡